Paper31270216
Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
Bruen R and 10 others. J Pharmacol Exp Ther, 2019. Cited by 47 papers, by iCite.
Cite this record
ConductScience Library. Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. Papers, record 31270216. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31270216
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apolipoproteins E | Major topic |
| Inflammation Mediators | Major topic |
| Liraglutide | Major topic |
| Phenotype | Major topic |
| Plaque, Atherosclerotic | Major topic |
| Animals | |
| Chemokines | |
| Disease Progression | |
| Female | |
| Humans | |
| Male | |
| Mice |
Source PubMed
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42738873 | Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists. | Cells | 2026 | https://conductscience.org/library/papers/42738873 | PubMed |
| 42461990 | GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight. | Circ Res | 2026 | https://conductscience.org/library/papers/42461990 | PubMed |
| 42390946 | A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes. | JCI Insight | 2026 | https://conductscience.org/library/papers/42390946 | PubMed |
| 42313337 | Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis. | Intern Emerg Med | 2026 | https://conductscience.org/library/papers/42313337 | PubMed |
| 41908941 | Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs). | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/41908941 | PubMed |
| 41482411 | Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review. | In Vivo | 2026 | https://conductscience.org/library/papers/41482411 | PubMed |
| 40870496 | The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40870496 | PubMed |
| 40826119 | Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies. | Diabetol Metab Syndr | 2025 | https://conductscience.org/library/papers/40826119 | PubMed |
| 40721629 | Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway. | Sci Rep | 2025 | https://conductscience.org/library/papers/40721629 | PubMed |
| 40149704 | Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation. | Biomedicines | 2025 | https://conductscience.org/library/papers/40149704 | PubMed |
| 39858999 | The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39858999 | PubMed |
| 39834741 | Bile acids and incretins as modulators of obesity-associated atherosclerosis. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/39834741 | PubMed |
| 39741663 | Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/39741663 | PubMed |
| 39528690 | Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients. | Sci Rep | 2024 | https://conductscience.org/library/papers/39528690 | PubMed |
| 39269643 | Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/39269643 | PubMed |
| 39062871 | Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39062871 | PubMed |
| 38970123 | Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia/reperfusion through modulating macrophages polarization. | Cardiovasc Diabetol | 2024 | https://conductscience.org/library/papers/38970123 | PubMed |
| 38720777 | Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38720777 | PubMed |
| 38384297 | Emerging role of antidiabetic drugs in cardiorenal protection. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38384297 | PubMed |
| 38136567 | Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born? | Biomolecules | 2023 | https://conductscience.org/library/papers/38136567 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCL2 | 6347 | PubTator's text mining | https://conductscience.org/library/genes/6347 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31270216
GET https://conductscience.org/api/papers/v1/31270216/cited_by?page=2